Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 25;10(9):1618.
doi: 10.3390/healthcare10091618.

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

Affiliations

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

Denis Horgan et al. Healthcare (Basel). .

Abstract

Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and care. However, take-up is uneven, research needs and potential outstrip currently available resources, manifestly beneficial practices-such as population-level screening for lung cancer-are still not generalised, and the quality of life of patients and survivors is only beginning to be given attention it merits. This paper, mainly based on a series of multistakeholder expert workshops organised by the European Alliance for Personalised Medicine (EAPM), looks at some of those specifics in the interest of planning a way forward. Part of this exercise also involves taking account of the specific nature of Europe and its constituent countries, where the complexities of planning a way forward are redoubled by the wide variations in national and regional approaches to cancer, local epidemiology and the wide disparities in health systems. Despite all the differences between cancers and national and regional resources and approaches to cancer care, there is a common objective in pursuing broader and more equal access to the best available care for all European citizens.

Keywords: EU Beating Cancer Plan, EBCP; access; cancer; citizens; healthcare; molecular diagnostics; patient; personalised medicine; policy framework; reimbursement; screening; treatment; unmet medical need.

PubMed Disclaimer

Conflict of interest statement

Paolo A. Asciero has/had the following conflict of interest not related to the work under consideration: consultant/advisory role for Bristol Myers Squibb, Roche Genentech, Merck-Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, Astra Zeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX. He also received research funding from Bristol Myers Squibb, Roche Genentech, Pfizer, Sanofi. Travel support by Pfizer. Thierry Andre declared honoraria/consulting or advisory role from Amgen, Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Chugai, Clovis, Gritstone Oncology, GlaxoSmithKline, Haliodx, Kaleido Biosciences, Merck&Co., Inc., Pierre Fabre, Roche/Ventana, Sanofi, Seagen, Servier; travel, accommodations, expenses-MSD Oncology, BMS; Jens Vogel-Claussen has/had the following conflict of interest not related to the work under consideration: research funding/honoraria/consulting or advisory role from Federal Ministry of Education and Research, Siemens Healthineers, Novartis, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline. Anne-Marie Baird is the President of Lung Cancer Europe (LuCE). This is an unpaid volunteer role. LuCE has received funding from Amgen, Astra Zeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Merck, MSD, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, Janssen, Novocure, ThermoFisher. Josep Malvehy declares fees for advisory boards, lectures in symposia and research grants from Almirall, BMS, Sunpharma, Pierre Fabre, Amgen, Castle bioscience, AMLO bioscience, ISDIN, Roche Posay. Marco Donia has received in the past three years honoraria for lectures from Roche and Novartis, access to online conference material from Merck Sharp Dome, access to proprietary data from Bristol Myers Squibb and Genentech and advisory fee from Achilles Therapeutics. Paul Van Schill: external expert and advisory board AstraZeneca, Janssen, MSD, Roche; treasurer BACTS (Belgian Association for Cardiothoracic Surgery); president-elect IASLC (International Association for the Study of Lung Cancer). France Dube is an employee of Astra Zeneca. Grazyna Kaminska-Winciorek has/had the following conflict of interest not related to the work under consideration: consultant/advisory role for MSD, Takeda; Travel support by Pierre Fabre, Roche, Bristol Myers Squibb; Speaker’s honoraria: Pierre Fabre, Novartis, Sanofi, Amgen, MSD, Takeda. Michael Zaiac is an employee of Novartis pharmaceuticals. D.H. and M.K. are employees of the European Alliance for Personalised Medicine, which receives funding from both the public and private sectors.

Similar articles

Cited by

References

    1. European Commission Europe’s Beating Cancer Plan. 2022. [(accessed on 2 June 2022)]. Available online: https://ec.europa.eu/health/system/files/2022-02/eu_cancer-plan_en_0.pdf.
    1. Nagai H., Kim Y.H. Cancer prevention from the perspective of global cancer burden patterns. J. Thorac. Dis. 2017;9:448–451. doi: 10.21037/jtd.2017.02.75. - DOI - PMC - PubMed
    1. European Commission EU Policy on Cancer. 2022. [(accessed on 2 June 2022)]. Available online: https://ec.europa.eu/health/non-communicable-diseases/cancer_en.
    1. Horgan D., Baker M., Riegman P., Bernini C. Personalised Medicine-Bringing Innovation to the Healthcare System. Biomed. Hub. 2017;2:16–21. doi: 10.1159/000479674. - DOI - PMC - PubMed
    1. Horgan D., Ciliberto G., Conte P., Curigliano G., Seijo L., Montuenga L.M., Garassino M., Penault-llorca F., Galli F., Ray-coquard I., et al. Bringing onco-innovation to Europe’s healthcare systems: The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine. Cancers. 2021;13:583. doi: 10.3390/cancers13030583. - DOI - PMC - PubMed

LinkOut - more resources